Concord Drugs Ltd - 538965 - Declaration Of Financial Results For Quarter Ended 30.06.2024
Submission of Financial Results for Quarter ended 30.06.202409-08-2024
09-08-2024
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited(Standalone & Consolidated) Financial Results For 1St Quarter, 2024 .
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 ,inter alia, to consider and approve Concord Drugs Ltd has informed BSE that the meeting of the Board of directors Meeting is scheduled on 09th August 2024 for Approval of Unaudited(Standalone & Consolidated) Financial Results for 1st Quarter, 2024 and to consider any other matter by permission of Chair03-08-2024
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI(DP) Regulations, 2018.16-07-2024
Concord Drugs Ltd - 538965 - Closure of Trading Window
Intimation of Closure of Trading Window30-06-2024
Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of News Paper Publication.01-06-2024
Concord Drugs Ltd - 538965 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for year ending 31st March, 2024.30-05-2024
Concord Drugs Ltd - 538965 - Results For Financial Year Ending March 31St 2024
Audited Results for Financial year ending March 31st 202430-05-2024
Concord Drugs Ltd - 538965 - Board Meeting Outcome for Audited Results For Financial Year 2023-2024
Audited Results for Financial year 2023-202430-05-2024
Concord Drugs Ltd - 538965 - Update on board meeting
The Board Meeting to be held on 25/05/2024 has been revised to 30/05/2024 The Board Meeting to be held on 25/05/2024 has been revised to 30/05/202424-05-2024